Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
Alkermes Plc (NASDAQ:ALKS) has enjoyed a relatively strong Street backing over the last six months despite its nearly 40-percent drop. On Wednesday, though, it caught a downgrade, bringing its ratings mix to six Buys, five Holds and two Sells, according to TipRanks.
The Rating
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Goldman Sachs analyst Terence Flynn cut Alkermes from Neutral to Sell and lowered his price target from $49 to $26.
The Thesis
Flynn removed two key elements from its model: sales of ALKS-5461 for depression and the potential for merger activity.
“We expect FDA to issue a complete response letter (i.e., non-approval) on or before the Jan 31 PDUFA date and we don’t expect Study 217 to be sufficient to address potential FDA issues following the negative Adcom outcome (11/1),” he said of the depression candidate.
Want Private Access to Benzinga Analyst?
Check out the latest strategies our team of experts are using every week so that you can always adapt to the market like the pros!—Get FULL Access to This Week's Webinar Here.
Additionally, channel checks suggest the schizophrenia treatment, ALKS-3831, posts unfavorable metabolic and weight-gain data and will not likely transform treatment.
“The level of SG&A investment ahead of a potential ‘3831 launch is underappreciated (we raise our expenses and are now 9%-15% higher than consensus in 2019-2021),” the analyst wrote in the note.
Flynn would take a more bullish stance on the stock if Alkermes could better differentiate the ALKS-3831 metabolic profile from Zyprexa; secure FDA approval of ALKS-5461; drive leverage in Vivitrol sales; outperform estimates for Aristada; or posts strong activity for ALKS-4230 in cancer treatment.
Price Action
At time of publication, Alkermes shares were down 3.4 percent at $30.72.
Related Links:
FDA Committees' Unfavorable Ruling Depresses Alkermes Shares
Alkermes Falls 20% After FDA Refusal To File Letter
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.